Micro
Emerging
Active
VRDN wider loss in Q4 FY25
New narrative with limited coverage — still forming.
Score
0.2
Velocity
▲ 0.0
Articles
3
Sources
2
Top Movers
| Ticker | Sector | Change |
|---|---|---|
| Healthcare | +20.7% |
Sentiment Timeline
Sector Performance
Stock Performance
Event Timeline
Top Movers
| Ticker | Sector | Change |
|---|---|---|
| Healthcare | +20.7% |
🤖
AI Overview
What happened: Veradermics, Inc. (NYSE:MANE) reported a Q4 net loss of $21.8M on March 30, 2026, ending the year with $141.9M in cash. Nurix Therapeutics, Inc. (NRIX) posted a wider Q1 net loss of $87.2M, with revenue dropping to $6.3M from $18.5M the previous year.
Market impact: The widening losses and revenue declines at these biotech companies could signal a slowdown in the sector, potentially impacting other small-cap biotechs and healthcare stocks. Investors may reassess their portfolios, leading to a valuation repricing.
What to watch next: Veradermics' Q1 2027 earnings on June 30, 2027, and Nurix's Q2 2027 earnings on August 15, 2027, will provide updates on their financial health. Additionally, any regulatory decisions on their pipeline drugs will significantly influence their stocks.
Market impact: The widening losses and revenue declines at these biotech companies could signal a slowdown in the sector, potentially impacting other small-cap biotechs and healthcare stocks. Investors may reassess their portfolios, leading to a valuation repricing.
What to watch next: Veradermics' Q1 2027 earnings on June 30, 2027, and Nurix's Q2 2027 earnings on August 15, 2027, will provide updates on their financial health. Additionally, any regulatory decisions on their pipeline drugs will significantly influence their stocks.
AI Overview as of Apr 12, 2026
Timeline
First SeenMar 30, 2026
Last UpdatedMar 30, 2026